(Q38978632)

8 September 2017

1 reference

title

Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (English)

1 reference

8 September 2017

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Robert S. Langer, Jr.

series ordinal

4

object named as

Robert Langer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1

Héloïse Ragelle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Véronique Préat

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Daniel G Anderson

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

12 October 2016

1 reference

Expert Opinion on Drug Delivery

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

851-864

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

Cancer nanomedicines: so many papers and so few drugs!

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Emerging Frontiers in Drug Delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

The emerging nanomedicine landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Strategies in the design of nanoparticles for therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Nanomedicine in cancer therapy: innovative trends and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Doxil®--the first FDA-approved nano-drug: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

EPR: Evidence and fallacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Challenges in development of nanoparticle-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Critical questions in development of targeted nanoparticle therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Non-viral vectors for gene-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Delivery materials for siRNA therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Development of lipidoid-siRNA formulations for systemic delivery to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Impact of nanotechnology on drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Nanoscale radiotherapy with hafnium oxide nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Quality by design for biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Methods for the preparation and manufacture of polymeric nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Dose escalation methods in phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Trial watch: phase II and phase III attrition rates 2011-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Key cost drivers of pharmaceutical clinical trials in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Regulatory aspects on nanomedicines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

In vitro and in vivo characterizations of PEGylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

Progress in material design for biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2016.1244187

10.1080/17425247.2016.1244187

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27730820%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference